As the impact of ischemia reperfusion injury on graft outcome is now well defined, efforts are made towards decreasing these lesions, typically through the improvement of preservation techniques.
The use of pharmacological supplements which could be compatible with any preservation solution used by the transplant center and target specific pathways of IR is an interesting strategy to improve graft quality. However, the extensive number of studies showing the benefits a molecule in an animal model of IR without thorough mechanistic determination of the effects of this agent make it difficult to opt for specific pharmaceutical intervention. Herein we expose studies which demonstrate the benefits of several molecules relying on a thorough mechanical analysis of the events occurring during preservation, both at the cellular and the systemic levels. We believe this approach is the most appropriate to truly understand the potential benefits of a molecule and particularly to design a comprehensive pharmaceutical regiment, with several agents acting synergistically against IR, to improve organ preservation and graft outcome.
Written by:
Saint Yves T, Delpech PO, Giraud S, Thuillier R, Hauet T. Are you the author?
Inserm U1082, université de Poitiers, CHU La Miletrie, 86000 Poitiers, France; Service d'Urologie, CHU La Miletrie, 86000 Poitiers, France.
Reference: Prog Urol. 2014 Jun;24 Suppl 1:S31-6.
doi: 10.1016/S1166-7087(14)70061-2
PubMed Abstract
PMID: 24950930
UroToday.com Renal & Vascular Diseases Section
